It intends ABO-101 to durably reduce oxalate levels by knocking down a gene called HAO1. The medicine contains nucleic acid ...

Arbor Biotechnologies has closed $73.9m for its gene editing therapeutic pipeline aimed at liver and central nervous system ...

A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...

ABO-101 is designed to knock down HAO1 gene expression ... is advancing a pipeline of novel gene editing therapeutics to address a wide range of genetic conditions – from the ultra-rare to ...

US genetic medicines firm Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support ...

The gene therapy world is in turmoil, but Arbor, armed with more than $1 billion in partnerships and raises, is going forward.

The proceeds will support clinical development of the company's lead therapeutic candidate, ABO-101, in primary hyperoxaluria ... of potentially curative genetic medicines for patients,” said ...

Trump declares tariffs will be ‘best thing’ US has ever done - but refuses to rule out a recession Angels Superstar Mike Trout Makes Feelings Clear on Playing for Team USA in 2026 World ...

Light bulbs did in fact replace candles' Prince Frederik dies from rare genetic condition at age 22. See his dad's emotional message What happens after a city removes a freeway? NFL News ...

In an attempt to bolster organ and tissue donation, the Telangana government has decided to adopt the Transplantation of Human Organs and Tissues Act (THOTA) ...